we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
Company profile
Ticker
KRTX
Exchange
Website
CEO
Steven Marc Paul
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Karuna Securities Corporation ...
IRS number
270605902
KRTX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
28 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
18 Mar 24
25-NSE
Exchange delisting
18 Mar 24
POSASR
Automatic shelf registration (post-effective amendment)
18 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
18 Mar 24
10-K/A
2023 FY
Annual report (amended)
14 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
22.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 38 |
Opened positions | 10 |
Closed positions | 230 |
Increased positions | 10 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 71.54 bn |
Total shares | 8.67 mm |
Total puts | 0.00 |
Total calls | 701.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
ARCH Venture Fund IX | 2.91 mm | $323.47 mm |
PRTC PureTech Health | 2.41 mm | $277.96 mm |
PureTech Health | 1.53 mm | $0.00 |
Sofinnova Venture Partners X | 1.38 mm | $331.62 mm |
SG Americas Securities | 174.19 k | $55.13 mm |
Allspring Global Investments | 102.09 k | $32.31 bn |
Catalyst Private Wealth | 77.86 k | $24.64 bn |
DekaBank Deutsche Girozentrale | 20.00 k | $6.33 mm |
Arizona State Retirement System | 8.95 k | $2.83 bn |
Hennion & Walsh Asset Management | 8.76 k | $2.77 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Laurie J Olson | Common Stock | Sale back to company | Dispose D | No | No | 330 | 990 | 326.70 k | 0 |
18 Mar 24 | Laurie J Olson | Option Common Stock | Sale back to company | Dispose D | No | No | 92.3 | 1,904 | 175.74 k | 0 |
18 Mar 24 | Laurie J Olson | Option Common Stock | Sale back to company | Dispose D | No | No | 227.04 | 5,000 | 1.14 mm | 0 |
18 Mar 24 | Laurie J Olson | Option Common Stock | Sale back to company | Dispose D | No | No | 201.99 | 8,500 | 1.72 mm | 0 |
18 Mar 24 | Laurie J Olson | Option Common Stock | Sale back to company | Dispose D | No | No | 245.14 | 13,000 | 3.19 mm | 0 |
18 Mar 24 | Paul Steven M | Common Stock | Sale back to company | Dispose D | Yes | No | 330 | 35,877 | 11.84 mm | 0 |
18 Mar 24 | Paul Steven M | Common Stock | Sale back to company | Dispose D | Yes | No | 330 | 30,304 | 10.00 mm | 0 |
18 Mar 24 | Paul Steven M | Common Stock | Sale back to company | Dispose D | Yes | No | 330 | 33,882 | 11.18 mm | 0 |
18 Mar 24 | Paul Steven M | Common Stock | Sale back to company | Dispose D | Yes | No | 330 | 10,000 | 3.30 mm | 0 |
18 Mar 24 | Paul Steven M | Common Stock | Sale back to company | Dispose D | Yes | No | 330 | 30,304 | 10.00 mm | 0 |
News
HC Wainwright & Co. Maintains Neutral on Karuna Therapeutics, Maintains $330 Price Target
14 Mar 24
HC Wainwright & Co. Reiterates Neutral on Karuna Therapeutics, Maintains $330 Price Target
11 Mar 24
Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect
27 Feb 24
Karuna Therapeutics: Q4 Earnings Insights
22 Feb 24
Karuna Therapeutics Q4 EPS $(3.01) Misses $(2.65) Estimate
22 Feb 24
Press releases
PureTech Announces Annual Results for Year Ended December 31, 2023
25 Apr 24
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
22 Feb 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KRTX, SNCE, KAMN, BATL
15 Feb 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates GMGI, KRTX, SIX, AVRO
15 Feb 24
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
14 Feb 24